Ajai Chari, MD, associate professor, Mount Sinai Hospital, discusses some of the recent clinical trial evidence for early relapsed multiple myeloma and how it can be put into practice.
Age, Disease Burden Are Factors in Early Use of Selinexor in Multiple Myeloma
April 22nd 2024During a Case-Based Roundtable® event, Jonathan L. Kaufman, MD, discussed treatment approaches and the tolerability of a selinexor-containing regimen in a patient with relapsed/refractory multiple myeloma in the first article of a 2-part series.
Read More